NF-κB activation: nondegradative ubiquitination implicates NEMO

Trends in Immunology

Volumn 27, Issue 9, 2006, Pages 395-397

  Israël, Alain ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSINE; PROTEIN; RECEPTOR INTERACTING PROTEIN 1; UNCLASSIFIED DRUG; I KAPPA B KINASE; UBIQUITIN;

DOWN REGULATION; ENZYME ACTIVATION; SHORT SURVEY; UBIQUITINATION; ARTICLE; IMMUNOLOGY; METABOLISM;

ENZYME ACTIVATION; I-KAPPA B KINASE; NF-KAPPA B; UBIQUITINS;

EID: 33747065618     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2006.07.003     Document Type: Short Survey

References (17)

1. Bonizzi G., and Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25 (2004) 280-288
2. Hayden M.S., and Ghosh S. Signaling to NF-κB. Genes Dev. 18 (2004) 2195-2224
3. Chen Z.J. Ubiquitin signalling in the NF-κB pathway. Nat. Cell Biol. 7 (2005) 758-765
4. Kanayama A., et al. TAB2 and TAB3 activate the NF-κB pathway through binding to polyubiquitin chains. Mol. Cell 15 (2004) 535-548
5. Wu C.J., et al. NEMO is a sensor of Lys63-linked polyubiquitination and functions in NF-κB activation. Nat. Cell Biol. 8 (2006) 398-406
6. Ea C.K., et al. Activation of IKK by TNFα requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol. Cell 22 (2006) 245-257
7. Li H., et al. Ubiquitination of RIP is required for TNFα-induced NF-κB activation. J. Biol. Chem. 281 (2006) 13636-13643
8. Habelhah H., et al. Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-κB. EMBO J. 23 (2004) 322-332
9. Hicke L., et al. Ubiquitin-binding domains. Nat. Rev. Mol. Cell Biol. 6 (2005) 610-621
10. Wertz I.E., et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 430 (2004) 694-699
11. Brummelkamp T.R., et al. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 424 (2003) 797-801
12. Kovalenko A., et al. The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination. Nature 424 (2003) 801-805
13. Trompouki E., et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature 424 (2003) 793-796
14. Massoumi R., et al. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-κB signaling. Cell 125 (2006) 665-677
15. Sato S., et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat. Immunol. 6 (2005) 1087-1095
16. Shim J.H., et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 19 (2005) 2668-2681
17. May M.J., et al. A novel ubiquitin-like domain in IκB kinase β is required for functional activity of the kinase. J. Biol. Chem. 279 (2004) 45528-45539